Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

B. Lowenberg, J. Beck, C. Graux, W van Putten, H.C. Schouten, L.F. Verdonck, A Ferrant, P. Sonneveld, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B.J. Biemond, E. Vellenga, D. Breems, H. de Muijnck, R. Schaafsma, G. Verhoef, H. Dohner, A. Gratwohl, T. Pabst, G.J. Ossenkoppele & 1 others J. Maertens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2586-2591
JournalBlood
Volume115
Issue number13
DOIs
Publication statusPublished - 2010

Cite this

Lowenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H. C., Verdonck, L. F., ... Maertens, J. (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), 2586-2591. https://doi.org/10.1182/blood-2009-10-246470
Lowenberg, B. ; Beck, J. ; Graux, C. ; van Putten, W ; Schouten, H.C. ; Verdonck, L.F. ; Ferrant, A ; Sonneveld, P. ; Jongen-Lavrencic, M. ; von Lilienfeld-Toal, M. ; Biemond, B.J. ; Vellenga, E. ; Breems, D. ; de Muijnck, H. ; Schaafsma, R. ; Verhoef, G. ; Dohner, H. ; Gratwohl, A. ; Pabst, T. ; Ossenkoppele, G.J. ; Maertens, J. / Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. In: Blood. 2010 ; Vol. 115, No. 13. pp. 2586-2591.
@article{1eda5722d7c04e119e4d65b71fcd5abf,
title = "Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study",
author = "B. Lowenberg and J. Beck and C. Graux and {van Putten}, W and H.C. Schouten and L.F. Verdonck and A Ferrant and P. Sonneveld and M. Jongen-Lavrencic and {von Lilienfeld-Toal}, M. and B.J. Biemond and E. Vellenga and D. Breems and {de Muijnck}, H. and R. Schaafsma and G. Verhoef and H. Dohner and A. Gratwohl and T. Pabst and G.J. Ossenkoppele and J. Maertens",
year = "2010",
doi = "10.1182/blood-2009-10-246470",
language = "Undefined/Unknown",
volume = "115",
pages = "2586--2591",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

Lowenberg, B, Beck, J, Graux, C, van Putten, W, Schouten, HC, Verdonck, LF, Ferrant, A, Sonneveld, P, Jongen-Lavrencic, M, von Lilienfeld-Toal, M, Biemond, BJ, Vellenga, E, Breems, D, de Muijnck, H, Schaafsma, R, Verhoef, G, Dohner, H, Gratwohl, A, Pabst, T, Ossenkoppele, GJ & Maertens, J 2010, 'Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study' Blood, vol. 115, no. 13, pp. 2586-2591. https://doi.org/10.1182/blood-2009-10-246470

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. / Lowenberg, B.; Beck, J.; Graux, C.; van Putten, W; Schouten, H.C.; Verdonck, L.F.; Ferrant, A; Sonneveld, P.; Jongen-Lavrencic, M.; von Lilienfeld-Toal, M.; Biemond, B.J.; Vellenga, E.; Breems, D.; de Muijnck, H.; Schaafsma, R.; Verhoef, G.; Dohner, H.; Gratwohl, A.; Pabst, T.; Ossenkoppele, G.J.; Maertens, J.

In: Blood, Vol. 115, No. 13, 2010, p. 2586-2591.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

AU - Lowenberg, B.

AU - Beck, J.

AU - Graux, C.

AU - van Putten, W

AU - Schouten, H.C.

AU - Verdonck, L.F.

AU - Ferrant, A

AU - Sonneveld, P.

AU - Jongen-Lavrencic, M.

AU - von Lilienfeld-Toal, M.

AU - Biemond, B.J.

AU - Vellenga, E.

AU - Breems, D.

AU - de Muijnck, H.

AU - Schaafsma, R.

AU - Verhoef, G.

AU - Dohner, H.

AU - Gratwohl, A.

AU - Pabst, T.

AU - Ossenkoppele, G.J.

AU - Maertens, J.

PY - 2010

Y1 - 2010

U2 - 10.1182/blood-2009-10-246470

DO - 10.1182/blood-2009-10-246470

M3 - Article

VL - 115

SP - 2586

EP - 2591

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -